New heart valve device tested in humans for first time

NCT ID NCT05909748

Recruiting now Disease control Sponsor: Valve Medical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tests a new device called GEMINUS, which replaces a narrowed heart valve without open-heart surgery. It involves 30 people with severe aortic stenosis. The goal is to see if the procedure is safe and feasible, with follow-up for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEMINUS Transcatheter Aortic Valve Implantation (TAVI) system
What this could lead to: If successful, this could offer a new, less invasive option for replacing a narrowed heart valve, improving blood flow and symptoms.
What could go wrong: This is a very early, small study (30 people) testing safety and feasibility only. The device may not work as intended or could cause complications like bleeding or valve misplacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Locations

Rabin Medical Center
RECRUITING

Petah Tikva, Israel
Tel Aviv Sourasly Medical Center
NOT_YET_RECRUITING

Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.